Radioactive antibody hunt: could a new scan outsmart hidden kidney cancer?
NCT ID NCT06447103
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase II trial tests whether a special PET/CT scan using a radioactive tracer called 89Zr-DFO-girentuximab can find recurrent clear cell renal cell carcinoma after surgery better than standard contrast-enhanced CT. The tracer attaches to a protein (CAIX) on kidney cancer cells, making them visible on the scan. About 91 adults who had surgery for kidney cancer will be enrolled to compare the two imaging methods.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
89Zr-DFO-girentuximab (a radioactive tracer that attaches to CAIX protein on kidney cancer cells)
What this could lead to
If successful, this imaging method could detect recurrent kidney cancer earlier and more accurately than standard CT scans, potentially improving treatment decisions.
What could go wrong
This is a Phase II trial with only 91 participants, so results may not apply to all patients. The new tracer involves radiation exposure and may not detect all recurrences.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90095, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact